$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
How long can one live after gefitinib is used to treat advanced lung cancer?
2025-10-19 11:44:20
Check Details
What is the target of ceritinib?
2025-10-19 11:44:20
Check Details
What is the effect of AMG510 on non-small cell lung cancer?
2025-10-19 11:44:20
Check Details
Which generation of targeted drug is cabozantinib?
2025-10-19 11:44:20
Check Details
What is the objective response rate of TAK-788 in treating lung cancer?
2025-10-19 11:44:20
Check Details
Is it okay to take poziotinib after becoming resistant to osimertinib?
2025-10-19 11:44:20
Check Details
Which of the fourth generation lung cancer targeted drugs, Amivantamab or Mobocertinib, is more effective?
2025-10-19 11:44:20
Check Details
What is the efficacy of Amivantamab combined with Lazertinib?
2025-10-19 11:44:20
Check Details
What is the effect of Yiluake Tablets (Qixinke) in treating non-small cell lung cancer?
2025-10-19 11:44:20
Check Details
What diseases does Yiruake Tablets treat?
2025-10-19 11:44:20
Check Details
How effective is Yiluaq in treating lung cancer
2025-10-19 11:44:20
Check Details
What are the contraindications and precautions for treating lung cancer with Yiluaq
2025-10-19 11:44:20
Check Details
1
2
...
4130
4131
4132
4133
4134
4135
4136
...
4163
4164
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Weight Gain and Edema Management, Monitoring of Repotrectinib (Augtyro) During Treatment
2
How to Take Tucatinib (Tukysa): Dosing Schedule, Combination Use & Missed Dose Guidance
3
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
4
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
5
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
6
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
7
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
8
Selumetinib and KRAS Mutations: Where the MEK Inhibitor Actually Fits
9
Erdafitinib in Lung Squamous Cell Carcinoma: Indication Boundaries and FGFR Interpretation
10
Daraxonrasib (Rasonque): Chemical Identity and RAS Tri-Complex Mechanism
11
Tamoxifen and Feeling Older: Managing Hot Flashes, Fatigue, and Skin Changes
12
FDA Approves Pembrolizumab for TMB-H Solid Tumors: Threshold ≥13 mut/Mb, KEYNOTE-158 Data